Adjuvant radiotherapy is the standard treatment for early breast cancer after breast conserving surgery. Molecular subtypes was significantly associated with the risk of local recurrence of breast cancer. Nguyen et al found that the overall 5-year cumulative incidence of local recurrence was 0.8% for luminal A, 1.5% for luminal B, 8.4% for HER2 positive, and 7.1% for triple negative breast cancer after lumpectomy and radiotherapy. Her2 positive and triple negative breast cancers may be inherently radioresistant. Therefore, for HER2 positive and triple negative breast cancer with high local recurrence and radiation resistance, proton combined with carbon ion is proposed after breast conserving surgery.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
24
CTV1: whole breast, 40.05Gy(RBE) in 15 fractions with proton ion therapy; CTVboost: Tumor bed, carbon ion dose escalation study with four dose levels \[10.2Gy(RBE)/3Fx,10.8Gy(RBE) /3Fx,11.4Gy(RBE)/3Fx and 12Gy(RBE)/3Fx \].
Shanghai Proton and Heavy Ion center
Shanghai, China
RECRUITINGAcute toxicity
Treatment related acute toxicity assessed by CTCAE v4.03
Time frame: 3 months after the completion of CIRT
Local regional recurrence
The Ipsilateral breast and regional lymph nodes recurrence
Time frame: within 5 years after radiotherapy.
Cosmetic outcome as measured by Breast Cancer Treatment Outcomes Scale
Cosmetic outcome will be evaluated by Breast Cancer Treatment Outcomes Scale filled out by patients.
Time frame: within 5 years after radiotherapy.
Cosmetic outcome as measured by BCCT.core software
Patients' photographs of the breasts will be taken. With the use of BCCT.core software from The Breast Research group (INESC TEC) cosmetic outcome will be assessed.
Time frame: within 5 years after radiotherapy.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.